Teradata Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.7B-3.4% YoYTTM through 30 Jun 2026
Net Income $458M+301.8% YoYTTM through 30 Jun 2026
Free Cash Flow $736MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 59.4% |
| EBITDA Margin | 13.1% |
| Operating Margin | 12.3% |
| Net Margin | 27.1% |
Returns
77.2%ROE
27.6%ROA
255.9%ROIC
Balance Sheet Health
Debt / Equity2.40x
Current Ratio0.92x
Net Debt$58M
Cash & Equivalents$414M
Quality Metrics
Altman Z-Score1.40
Piotroski F-Score8 / 9
FCF Margin43.5%
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $1.7B
Diluted EPS$1.35TTMFY2025: $1.35
Dividend
No dividend
Capital Allocation
R&D Spend$290M
Capex Intensity1.5%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Product Sales | $1.5B | -2.7% | |
| Consulting Services | $201M | -19.0% |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.